Drugs / alpha-difluoromethylornithine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05594563 Comparator | Mar 2023 → Dec 2027 expected | type 1 diabetes mellitus | Emily K. Sims | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alpha-difluoromethylornithine | “DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase” PMID 3093066 ↗ Nov 1986 |
| Known as | DFMO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594563 ↗ |
| Known as | DL-alpha-difluoromethylornithine | “DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase” PMID 3093066 ↗ Nov 1986 |
| Action | Inhibit | “specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor” PMID 9719479 ↗ Apr 1998 |
| Route | Oral | “1000mg/m2/day oral DFMO” NCT05594563 ↗ |
| Target | ODC1 | “specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor” PMID 9719479 ↗ Apr 1998 |